{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:20Z","timestamp":1786119320013,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/cej.0b013e32832abd5e","type":"journal-article","created":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T03:18:25Z","timestamp":1254367105000},"page":"504-509","source":"Crossref","is-referenced-by-count":19,"title":["Prevalence and distribution of high-risk human papillomavirus in Greece"],"prefix":"10.1097","volume":"18","author":[{"given":"Theodoros","family":"Agorastos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros F.","family":"Lambropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Sotiriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themistoklis","family":"Mikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Togaridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos J.","family":"Emmanouilides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00008469-199504000-00006","article-title":"Epidemiology of human papillomavirus infection in Greek asymptomatic women","volume":"4","author":"Agorastos","year":"1995","journal-title":"Eur J Cancer Prev"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00008469-200404000-00010","article-title":"Cervical human papillomavirus infection in women attending gynaecological outpatient clinics in northern Greece","volume":"13","author":"Agorastos","year":"2004","journal-title":"Eur J Cancer Prev"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ygyno.2004.11.042","article-title":"Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience","volume":"96","author":"Agorastos","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2007\/147429","article-title":"HPV detection methods","volume":"23","author":"Brink","year":"2007","journal-title":"Dis Markers"},{"key":"R6-9-20210128","first-page":"1394","article-title":"Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types","volume":"11","author":"Castle","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1086\/428779","article-title":"A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica","volume":"191","author":"Castle","year":"2005","journal-title":"J Infect Dis"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1128\/JCM.00824-08","article-title":"Human papillomavirus genotype specificity of hybrid capture 2","volume":"46","author":"Castle","year":"2008","journal-title":"J Clin Microbiol"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-04-0812","article-title":"Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer","volume":"14","author":"Clifford","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/01.OLQ.0000080177.82204.E0","article-title":"Cervical human papillomavirus infection in the female population in Barcelona, Spain","volume":"30","author":"De Sanjose","year":"2003","journal-title":"Sex Transm Dis"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis","volume":"7","author":"De Sanjose","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/JCM.38.1.357-361.2000","article-title":"Improved amplification of genital human papillomaviruses","volume":"38","author":"Gravitt","year":"2000","journal-title":"J Clin Microbiol"},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jnci\/92.6.464","article-title":"Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica","volume":"92","author":"Herrero","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/ijc.23712","article-title":"Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark","volume":"123","author":"Kjaer","year":"2008","journal-title":"Int J Cancer"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1128\/JCM.38.1.408-411.2000","article-title":"Additional human papillomavirus types detected by the hybrid capture tube test among samples from women with cytological and colposcopical atypia","volume":"38","author":"Konya","year":"2000","journal-title":"J Clin Microbiol"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1017\/S095026880700876X","article-title":"Population-based study of human papillomavirus infection and cervical neoplasia in Athens, Greece","volume":"135","author":"Kroupis","year":"2007","journal-title":"Epidemiol Infect"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0890-8508(92)90059-7","article-title":"Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis","volume":"6","author":"Lungu","year":"1992","journal-title":"Mol Cell Probes"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.OLQ.0000085181.25063.6C","article-title":"Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study","volume":"30","author":"Matos","year":"2003","journal-title":"Sex Transm Dis"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/CEJ.0b013e328305a0a6","article-title":"Prevalence of human papillomavirus and Chlamydia trachomatis infection among women attending cervical cancer screening in the Republic of Korea","volume":"18","author":"Oh","year":"2009","journal-title":"Eur J Cancer Prev"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/jmv.21025","article-title":"Prevalence of human papillomavirus types 6, 11, 16, 18, 31, and 33 in a cohort of Greek women","volume":"79","author":"Panotopoulou","year":"2007","journal-title":"J Med Virol"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.virol.2005.04.002","article-title":"The carcinogenicity of human papillomavirus types reflects viral evolution","volume":"337","author":"Schiffman","year":"2005","journal-title":"Virology"},{"issue":"3","key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.vaccine.2006.05.110","article-title":"Chapter 12: Prophylactic HPV vaccines: underlying mechanisms","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1086\/373901","article-title":"Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand","volume":"187","author":"Sukvirach","year":"2003","journal-title":"J Infect Dis"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/JCM.38.2.651-655.2000","article-title":"Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture","volume":"38","author":"Vernon","year":"2000","journal-title":"J Clin Microbiol"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"R29-9-20210128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CEJ.0b013e32832abd5e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:00:55Z","timestamp":1786039255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00008469-200911000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0b013e32832abd5e","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}